<DOC>
	<DOCNO>NCT00992225</DOCNO>
	<brief_summary>The primary purpose study determine objective response rate ( complete partial response ) patient receive LY573636 metastatic breast cancer .</brief_summary>
	<brief_title>A Study LY573636 Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Patient receive 2-hour intravenous infusion study drug ( LY573636 ) every 28 day . Radiologic image scan perform first dose study drug every treatment . Patients assess clinical progression every visit response approximately every 56 day ( every cycle ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Received least 2 prior chemotherapy regimens metastatic breast cancer . Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy least 4 week . Patients receive wholebrain radiation must wait 90 day . Serious preexist medical condition . Have active central nervous system leptomeningeal metastasis . Current hematologic malignancy , acute chronic leukemia . Receiving Warfarin ( Coumadin ) . Have history radiation therapy involve 25 % bone marrow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Metastatic</keyword>
</DOC>